Directorate Update

RNS Number : 9568P

Redx Pharma plc

14 February 2019

 

REDX PHARMA PLC

("Redx" or "the Company")

Redx announces directorate update and grant of options

Alderley Park, 14 February 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that further to the announcement made on 19 November 2018, James Mead assumed his new role as Chief Financial Officer on 1 February 2019 and has become a member of Redx Pharma's Board of Directors.

In addition, the company announces that on 13 February 2019, options over 1,200,000 ordinary shares of 1p each in the share capital of the Company, were granted to James Mead, Chief Financial Officer, on the following basis:

Granted 1,200,000 Options under Redx's Enterprise Management Incentive Scheme. 

200,000 options are exercisable at a price of 13.75p and will vest immediately
200,000 options are exercisable at a price of 20p and will vest immediately
200,000 options are exercisable at a price of 27p and will vest on the 1-year anniversary of the grant,

200,000 options are exercisable at a price of 35p and will vest on the 1-year anniversary of the grant,
200,000 options are exercisable at a price of 42.5p and will vest on the 2-year anniversary of the grant.
200,000 options are exercisable at a price of 50p and will vest on the 2-year anniversary of the grant.

None of these options will become exercisable until the second anniversary of grant. 

For further information, please contact:

Redx Pharma Plc	T: [phone]
Lisa Anson, Chief Executive Officer
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)	T: [phone]
Phil Davies
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting	T: [phone]
Simon Conway/Stephanie Cuthbert

About Redx Pharma Plc 

Redx is a UK biotechnology Group whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities. 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	James Mead
2	Reason for notification
a.	Position/Status	Chief Financial Officer
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Redx Pharma Plc
b.	LEI	213800HMS4EBXO589Y37
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over Ordinary Shares of 1p each ISIN: GB00BSNB6S51
b.	Nature of the transaction	Grant of options under the EMI Share Scheme
c.	Price(s) and volume(s)	Granted 1,200,000 Options under Redx's Enterprise Management Incentive Scheme. 200,000 options are exercisable at a price of 13.75p and will vest immediately 200,000 options are exercisable at a price of 20p and will vest immediately 200,000 options are exercisable at a price of 27p and will vest on the 1-year anniversary of the grant, 200,000 options are exercisable at a price of 35p and will vest on the 1-year anniversary of the grant, 200,000 options are exercisable at a price of 42.5p and will vest on the 2-year anniversary of the grant. 200,000 options are exercisable at a price of 50p and will vest on the 2-year anniversary of the grant.
d.	Aggregated information - Aggregated Volume - Price	N/A - Single Transaction
e.	Date of the transaction	13/02/2019
f.	Place of the transaction	Outside of trading venue

 

END

 

 

BOASFUSSLFUSEFE